New & Noteworthy!

ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026


ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • CRHCP, SHASTA-3/4: Advances in Dementia and Triglyceride Management
    The results from two Hot Line trials presented at ESC Congress 2026 hold promise for patients with high blood pressure (BP) at risk of dementia, and for patients with severe hypertriglyceridemia.
  • IDEAL-AF, NEXAF, PVI-SHAM-AF Provide New Evidence on Interventions That Could Improve AFib Management
    Three new studies presented during ESC Congress 2026 are shedding light on how best to treat and manage atrial fibrillation (AFib). From catheter ablation strategies to rhythm-control procedures and tailored exercise programs, the IDEAL-AF, NEXAF and PVI-SHAM-AF trials provide fresh evidence on interventions that could improve outcomes and quality of life.
  • JACC Late-Breaking Science Explores PET Imaging, HELIOS-B, DAPA ACT HF-TIMI 68 Analyses
    Late-breaking science presented at ESC Congress 2026 and simultaneously published in JACC Journals explore the performance of 124I-evuzamitide PET/MRI in patients with established or suspected cardiac amyloidosis (CA), treatment effect of vutrisiran by baseline tafamidis use, and impact of dapagliflozin on congestion in patients hospitalized for heart failure (HF).
  • TAVI PCI, ACASA-TAVI, TRIC-I-HF: New Answers in Structural Heart Care
    Three late-breaking trials presented at ESC Congress 2026 offer new insights into the management of structural heart disease and heart failure (HF), spanning coronary revascularization during TAVI, transcatheter treatment of tricuspid regurgitation, and post-TAVI antithrombotic therapy. Together, the TAVI PCI, ACASA-TAVI and TRIC-I-HF studies provide important evidence to help refine treatment strategies and improve patient […]
  • NOTION-4: Short-Term DOAC Therapy and Subclinical Leaflet Thickening Post TAVR
    A three-month direct oral anticoagulant (DOAC) regimen shortly after successful TAVR substantially reduced hypoattenuated leaflet thickening (HALT) during treatment vs. single antiplatelet therapy (SAPT) alone, based on findings from the NOTION-4 trial presented at ESC Congress 2026 and simultaneously published in JACC. However, researchers noted that this effect was diminished around nine months following discontinuation […]